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Gastrin is both stimulatory and trophic to the cells ofthe gastric fundus-parietal and peptic
cells, and enterochromaffin-like (ECL) cells which are major intermediaries of the gastrin
effect. Gastrin (from the antrum) and acid (from the fundus) represent the interactive positive
and negative limbs of a feedback loop. The nature and extent of sub-loops, perhaps involving
thevagus, acetylcholine, histamine, and otherpeptides and cell products are at present unclear
or unknown.
Loss of either gastrin or acid has predictable consequences. Absent acid, as in pernicious
anemia or as a result ofomeprazole, leads to hypergastrinemia. In rats, such hypergastrinemia
(gastrin > 1,000 pg/ml) causes fundic ECL hyperplasia and, eventually, carcinoids; in humans
with pernicious anemia, hypergastrinemia causes ECL-cell hyperplasia, which may progress to
carcinoids that are reversible upon withdrawal of gastrin, illustrated by three cases described
here. Loss ofgastrin by antrectomy for duodenal ulcer leads to fundic involution and marked
reduction in basal acid output, maximal acid output, and fundic histamine. An uncontrolled
excess of gastrin, as from a gastrinoma outside the negative feedback loop, causes acid and
pepsin hypersecretion with upper GI mucosal damage, the Zollinger-Ellison syndrome. This
paper summarizes the abnormal regulation ofgastrin and the biology, natural history, diagno-
sis, and management ofZE syndrome by medical and surgical means.
INTRODUCTION
Aswith other hormones (e.g.,ACT'H, TSH), gastrin has twofunctions, stimulation
and trophism (Fig. 1). Moreover, gastrin has multiple targets. The most evident
target for these actions ofgastrin is theparietal cell ofthegastricfundus, the product
of which, acid, completes the negative feedback loop by inhibiting the source of
gastrin, the G cell. Trophism of parietal cells is presumably controlled by the same
feedback mechanism, namely acid, even though stimulation and trophism may not
result from the same cellular mechanisms. It is not clear whether parietal cell
hyperplasia continues underthe influence ofhypergastrinemiawhile acid secretion is
inhibited by proton pump inhibitors, i.e., whether the replication and function
signals interact.
A second target of gastrin is the enterochromaffin-like (ECL)-cell population of
the gastric fundus, a function brought to light by the recent finding that profound
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acid suppression by the proton-pump inhibitor omeprazole or high-dose H2 antago-
nists [1] orneartotalfundectomy [2] in rats causesmarked hypergastrinemia, leading
to ECL-cell proliferation that eventually results in the development of ECL carci-
noids. It is not yet clear whether ECL cells represent a separate target or an
intermediate target-the pathway by which gastrin stimulates the parietal cell
through the release of histamine [3,4]. In the latter case, the feedback loop model
can be expanded (Fig. 1B); the eventual target product, acid, would serve as the
single negative link for stimulation and trophism ofboth ECL and parietal cells. In
addition to thegastricmucosa, gastrin is also trophic to the duodenal mucosa and the
pancreas, allofwhich canbe sustained in hypophysectomized ratsbygastrin alone. It
is not known what if any feedback products or loops are involved in these trophic
functions ofgastrin, but itisclearthatneitherduodenal mucosa northe pancreas are
subject to hyperplasia due to hypergastrinemia.
It is also not knownwhether there are anysub-loop direct feedbacks involved (e.g.,
between parietal cells and ECL cells), and whether other intermediaries such as
somatostatin, or the vagus, should be included in a further expanded model of the
feedback loop (Fig. 1B). It is, however, known from experimental and clinical data
that interruption or overactivity of the loop at either end (acid or gastrin) has
predictable consequences.
ACID AND THE ANTRUM
Gastrin, the product of antral G cells (source product) reaches its targets via the
circulation (i.e., hormonal), while the ultimate target product, acid, reaches the G
cell via the gastric lumen. This simple two-product closed loop may be disrupted at
either end. Thus, if acid is removed or diverted from the G cells, G cells will both
multiply and secrete gastrin in an unregulated manner, with resulting hypergas-
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FIG. 2. Effects ofantral acidification (HCl) on gastrin release stimulated viavagal activation
by 2-DG (2-deoxy-d-glucose) in the intact stomach [panel (a)], or after fundic vagotomy (FV)
[panel (b)]. In panel (c), the effect offood without and with acid instilled in the stomach, and in
panel (d) the lack of effect of acid in the stomach on the stimulation of gastrin release by the
bombesin nonapeptide analog given intravenously. All experiments performed in conscious
gastric fistula dogs (n = 4, mean ± SEM).
trinemia. Effective loss of acid results if parietal cells are lost (e.g., pernicious
anemia) or are rendered incapable of secreting acid by powerful inhibitors such as
omeprazole; the same outcome results if the antrum is removed from exposure to
acid experimentally by transplantation to the colon or the duodenum with acid
diversion [5,6]. In either case, the antrum still retains the essential mechanisms for
responding to acid suppression.
Implicit in this model is that acid isboth antisecretory and antitrophic for antral G
cells, but neither ofthe mechanisms driving G-cell secretion and trophism nor those
mediating the antisecretory effects of acid on gastrin release are known. Acid
(pH <2.0) inhibits gastrin release caused by food in the lumen, which is the major
stimulus of the G cell, as well as that produced by strong vagal stimulation (by the
compound 2-DG) in the dog (Fig. 2); however, gastrin release induced by the
neurotransmitter bombesin is insensitive to acid (Fig. 2). By contrast, somatostatin
inhibits bombesin- but not food-stimulated gastrin release [7], implying that there is
more than one antisecretory mechanism for the G cell and making it unlikely that
acid suppresses food-stimulated gastrin release via somatostatin from D cells. Since
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the G cell has a microvillous border opening to the lumen [8], it is possible that both
the stimulus (food, amines, peptides, and so on) and inhibitor (acid) act on this
surface. The cellular transduction pathways for either food or acid acting on this cell
surface membrane have not yet been described. Other negative feedback mecha-
nisms whereby acid inhibits gastrin release apparently originate in the duodenum.
Those would appear to be hormonal as well, since they reduce gastrin produced by a
colon-transplanted antral pouch [6].
To find a role for the intimately and strategically located inhibitory antral D
(somatostatin) cell, which is also an "open" type of cell with a lumenal microvillous
border as opposed to the closed D cells of the fundus [8], one could imagine the G
cell to be constitutively active but restrained by the antral D cell. Inhibition of the D
cell could then result in gastrin release, but, as argued above, acid does not seem to
act via the D cell, since somatostatin does not inhibit food-stimulated gastrin release
[7]. Since gastrin also stimulates the D cell, there may be a direct sub-loop by which
local release ofgastrin stimulates the D cell [9] and so additionally modulates gastrin
secretion. The role of bombesin and acetylcholine, both stimuli of the D cell as well
as the G cell (probably with different sensitivity) in regulating and modulating G-cell
secretion and proliferation, remains incompletely understood [9].
HYPERGASTRINEMIA AND THE FUNDUS
As displayed in Fig. 3, two principal gastric consequences arise from unregulated
hypergastrinemia: (1) With an atrophic fundus as in pernicious anemia in which
parietal cells are destroyed by an autoimmune process (Fig. 3a), ECL-cell hyperpla-
sia results, in some patients progressing to ECL carcinoids. In this case, the
hypergastrinemia is secondary to the loss ofthe normal acid feedback loop. (2) In the
presence of a gastrinoma, with a normal stomach, hypersecretion of acid and
hyperplasia ofparietal cells define the Zollinger-Ellison syndrome (Fig. 3b).
ECL-Carcinoid in PemiciousAnemia
Serum gastrin levels in pernicious anemia commonly exceed 1,000 pg/ml. As in
omeprazole-treated achlorhydric rats (Fig. 3a) with similarly high and unremitting
serum gastrin [1], ECL hyperplasia is common in patients with pernicious anemia
and about 5 percent develop multi-centric carcinoids [10]. Because a small propor-
tion of these may metastasize [11,12], total gastrectomy is often advised [13]. Two
reports [14,15] of regression of multi-centric carcinoids after removal of the gastrin
source by antrectomy, however, led us to recommend the same operation in three
similar patients [16]. All three patients (two males age 59 and 73 years and one
female age 45 years) had serum gastrin levels of approximately 1,500 pg/ml and had
been known to have carcinoids for six months to four years. Antrectomy was
performed in each, and serum gastrin fell to the normal range with a half-life of
40-60 minutes. In all three patients, carcinoids regressed rapidly, disappearing in
two at six weeks and in the third by four months. In all three, a micro-focus of
carcinoid was found at 14-18 months post-antrectomy but not in later follow-up, up
to 36 months after surgery. No ECL hyperplasia remained in any of the three
patients.
These results strongly support the concept that ECL-cell hyperplasia and carci-
noid are totally dependent on hypergastrinemia. This concept derived from the
evidence of ECL hyperplasia in rats due to hypergastrinemia induced by different
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FIG. 3. Fourclinical orexperimental models demonstrating the consequencesofremoval orofexcessof
acid or gastrin on the stimulus targets ECL and parietal cells or the acid-feedback target, the G cells. A
role for thevagus is illustrated in each case. a. Loss ofacid secretion through inhibition byomeprazole
(2) or the loss of parietal cells in pernicious anemia (PA) (1) leads to gastrin excess and ECL-cell
hyperplasia or even carcinoid tumor. b. The effect ofunregulated excess ofgastrin from a gastrinoma
(ZE) tumor on ECL and parietal cell number and function. The tumor is not subject to acid feed-
back. c. Antrectomy removes gastrin with consequent involution of the ECL and parietal cell targets.
Vagotomy augments the effect. d. If the antrum is transplanted out of the acid feedback, e.g., to the
colon in the dog [5,6], gastrin is secreted in an unregulated manner. Antral exclusion in man produces the
same result. Par. parietal cell; Hist: histamine.
acid-suppressing drugs [1,17] or by fundectomy [2]. ECL hyperplasia and carcinoids
were prevented by antrectomy [1] and were reversed upon removal of the stimulus,
either by stopping omeprazole or by antrectomy after one year [1,18]. Surprisingly,
unilateral vagotomy apparently blocks development of ECL-cell hyperplasia on the
ipsilateral fundic half [17], suggesting a modulating or permissive role for either
acetylcholine or other neurotransmitter ofthe vagus (Fig. 3).
Zollinger-Ellison Syndrome
The essential fact in Zollinger-Ellison (ZE) syndrome isthat the hypergastrinemia
due to gastrinoma is engrafted on to a normal gastrointestinal (GI) tract and that
complete removal of the tumor allows the resumption of the normal state. Careful
study ofsuch reversal would allow us to understand the effects ofconstant hypergas-
trinemia on the otherwise normal stomach. Adequate inhibition ofacid secretion by
omeprazole first allowed us to understand what the acid and pepsin hypersecretion
of ZE do to the GI tract. Complex duodenal ulcer, esophagitis, and diarrhea due to
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acid inactivation of pancreatic enzymes and damage to the jejunum are readily
reversed by omeprazole, as discussed below. These consequences of excessive acid
and pepsin secretion perhaps define more clearly the role of acid and pepsin in a GI
tract that is not affected by the partlygenetically determined duodenal ulcer disease
syndrome. Since, in ZE, hyperplasia ofthe fundic mucosa is the resultofthe action of
gastrin on previously normal mucosa, itmight be expected that removal ofthe tumor
would reverse the trophic effects of the hypergastrinemia. Gastric secretion was
studied before and after removal of an apparently single functioning gastrinoma in
two women aged 46 and 56 years with two and three years, respectively, of clinical
symptoms (Fig. 4). Basal acid output (BAO) fell from 49 to 5.4mEq/hour in one and
from 27 to 8.2 mEq/hour in the other. Peak acid output (PAO) (representing
parietal cell mass) [19] fell from 51.5 to 20.6 mEq/hour and from 37.8 to 19.3
mEq/hour, respectively (normal female BAO <(8 mEq/hour and PAO <o38 mEq/
hour, n = 50 [unpublished]). These figures suggest that parietal cell mass had been
doubled in these two patients. Maximum pepsin outputs showed an equally sharp
decline in both. It is not known whether maximum pepsin output reflects peptic cell
populations, and limited data exist for peptic cell populations in either normals or in
patients with ulcer or gastrinoma. Apoptotic cell death [20] would equally well
explain the rapid reversal, upon withdrawal of gastrin, of parietal cell hyperplasia
inducedby the hypergastrinemia in the ZEpatient, who is essentially normalwithout
thegastrinoma. Similarrapid reversals occur afterwithdrawal ofstimuli inexperimen-
tally induced hyperplasia in the adrenal cortex, liver, kidney, and pancreas of
mammals [20].
It should be noted that an equally great fall (25-50 percent) occurs in PAO after
vagotomy in patients with duodenal ulcer (DU) (Fig. 5), despite increased serum
gastrin to between 100 and 200 pg/ml. It is not clearwhether that represents loss of a
separate trophic effect ofthe vagus or a necessarygastrin/vagal interaction.
664HYPERGASTRINEMIA
pentagastrin 6pg/kg S.C.
8 :MSF
a cx ' | /_lL(~~~~~~~~~~~~~n-*129)
E
0
2 | _ Vag (n-49)
Vag & Res
0 (~~~~~~~~~~~~~~n=42)
20 40 80 80 100 120 140 160 180
1517 Time (Min)
FIG. 5. Gastric acid secretion in the basal fasting state (0-60 minutes),
after vagal stimulation (60-120 minutes) by modified sham feeding (MSF)
for 15 minutes (60-75 minutes) and after pentagastrin injection (120-180
minutes) in 129 patients with duodenal ulcer (DU), normal controls
(n = 39), duodenal ulcer after vagotomy (Vag) without resection, or after
vagotomy and antrectomy (Vag & Res).
Whether the ECL cells of the fundus represent a separate or an intermediate
target forgastrin (Fig. 1) is not clear. In acid-secreting fundus, ECLhyperplasia due
to hypergastrinemia also occurs-ECL-cell counts are increased by 100 to 200
percent in ZE [21]-but more advanced manifestations, i.e., ECLcarcinoid, are rare
and, when present, are almost exclusively seen in the multiple endocrine neoplasia
(MEN-I) syndrome. When contrasted with the greater prevalence ofadvanced ECL
hyperplasia and carcinoid in pernicious anemia (PA) or in achlorhydric rats, it is
tempting to conclude that there might be a sub-loop feedback between parietal cells
and ECL cells via acid or some other parietal cell product such as HCO3, that is
antitrophic. It is unlikely that a product of the ECL cells themselves, such as
histamine, could be the feedback agent, since in the anacid mucosa of pernicious
anemia, progressive ECLhyperplasia leading to carcinoid is more prominent than in
the acid-secreting mucosa ofZE.
SystemicMastocytosis
One interesting model that might shed light on other possible antral and fundic
feedbackloops is systemic mastocytosis, inwhich there isboth an excess ofhistamine
and basal acid hypersecretion, as well as elevated maximum acid output, i.e., an
increased parietal cell mass. There should be suppression of antral G cells, serum
gastrin, and fundic ECLcells.
REDUCED GASTRIN AND THE FUNDUS
One of the puzzling results of antrectomy in experimental animals or in DU has
been the marked reduction in monoamine oxidase (MAO), which is much greater
than that aftervagotomy (Fig. 5). Combiningbothsurgical proceduresproduces even
more profound reduction in MAO (Fig. 5). Reduced MAO might result from
reduction in the number ofparietal cellsbut could result from reduction (involution)
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ofthe ECL-cell population (Fig. 3c) [18], through which gastrin may be acting [3,4].
In support of such a possibility, Fig. 6 shows a higher response to histamine than to
gastrin in the antrectomized dog from both innervated and denervated fundic
pouches [22]. Both responses are lower in the denervated (Heidenhain) pouch. The
effect of antrectomy in reducing ECL-cell counts supports this concept [1,17].
Further recent evidence comes from quantitative studies of ECL number and
function [18]. A role for the vagus in ECL hyperplasia has been suggested by the
finding that unilateral vagotomy retards or prevents ECL hyperplasia in rats given
large doses ofomeprazole [17]. The implication is not only that ECL-cell hyperplasia
is vagus-dependent, but that ECL function may also be vagus-dependent [17]. That
hypothesis could explain why vagotomy of the fundus depresses the response to
pentagastrin but not histamine [23]. Moreover, restoration of the effectiveness of
pentagastrin after vagotomy by acetylcholine [23] clearly implicates a combined role
for gastrin and acetylcholine in ECL function as well as in hyperplasia. Presumably
by having a direct effect on the parietal cells, histamine bypasses this step.
CLINICAL IMPLICATIONS OF THE ZE SYNDROME
Though reported to be relatively uncommon-estimates of yearly incidence vary
from 0.1 to 3 per million population [21]-the ZE syndrome is probably more
common than generally realized because it is not routinely sought or tested for. ZE
syndromecomprises two principal forms. Asporadic form, inwhichgastrinoma is the
onlytumor, accounts for 80 percent ofcases. The remaining 20 percentofcases occur
where gastrinoma is part of a (familial) multiple endocrine neoplasia syndrome
(MEN-I) inwhich other endocrine adenomas, especially parathyroid, co-exist.
Sporadic Gastninomas
The sporadic form of gastrinoma is due to a single adenoma in 20-50 percent of
cases, and to more than one tumor in the rest. Gastrinomas occur in the gastrinoma
triangle, an anatomic location bounded by the junction of the cystic and common
ducts, thejunction ofthe head and body ofpancreas, and thejunction ofthe second
and third part of the duodenum [24]. Although traditionally thought to be a
pancreatic tumor, as many as 30 percent of gastrinomas are located outside the
pancreas, largely in the duodenal wall or peripancreatic lymph nodes, in which they
may be primary rather than metastatic [21,24]. In a significant number of cases,
perhaps up to 30 percent, no tumor can be found at surgery; however, more
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meticulous surgery and experience have reduced this number to less than 10 percent
[21]. Even so, the belief that ZE syndrome could result from islet cell hyperplasia
(nesidioblastosis) is no longervalid. Rare casesofgastrinomas elsewhere, such asthe
ovary, have been reported. It is reported that one-third of gastrinomas have
metastases at diagnosis [21], and earlier reports described an even higherprevalence
ofmetastases. Metastases areusually described inlocalized lymph nodes (where they
may be primary, since excision may eliminate the hypergastrinemia), or the liver,
where they may stabilize (in one of my patients, multiple hepatic metastases have
remained stable for 21 years). In rapidly spreading tumors, there is spread as well to
bone [25] or skin. Rapid spread is invariably associated with fatal outcome in less
than two years and is usually manifest early in the course of the disease. The
significance ofthe spread to lymph nodes or even to liver is not quite clearbecause of
thevariable rate ofprogression. By contrast with the 34 percent ofmetastases found
at initial surgery for ZE syndrome at the NIH [21], only five of 50 patients (10
percent) in our own institution have died of malignancy in a two- to 25-year
follow-up.
Gastrinomas resemble carcinoids and are classified as APUDomas (amine precur-
sor uptake and decarboxylation). The stem cell from which they derive is unknown.
No gastrin cell is normallyfound in the pancreas. Gastrinomas have a heterogeneous
morphology, and it is usually not possible to distinguish, histologically, malignant
from non-malignant tumors. Many, ifnot most, gastrinomas also contain one ormore
other GI hormones, though those are seldom clinically significant. They include
insulin, human pancreatic polypeptide, glucagon, somatostatin, neurotensin, ACTH,
and gastrin-releasing peptide (bombesin), which can all be demonstrated immunocy-
tochemically [26]. It is also possible to find gastrin associated with insulinomas, but
without clinical ZE manifestations.
Gastrinomas contain various molecular forms of gastrin, predominantly G-17.
Otherproductsvaryfrombig-biggastrin (larger than 34 amino acids) to G-34 [27], to
fragments ofgastrin and incompletely processed post-translational products such as
glycine-extended gastrin [28]. In all likelihood, these products represent variable
processing by the tumor cells. Blood concentrations of G-34 exceed those of G-17,
even though the tumors contain less, because of a longer half-life of G-34. The ratio
ofG-34: G-17 has not been shown to have anyclinical significance.
MEN-I
About 20 percent ofpatients with ZE syndrome have familial MEN-I [21,29]. The
associated endocrine tumors are parathyroid (80percent), beta cell islet (insulin) (20
percent), and, less commonly, glucagonoma, VIPoma, and others ( <5 percent) [26].
Pituitary adenomas occur in 50-60 percent and adrenal tumors in 27-36 percent,
although many arenon-functional. The mosttypical finding, related to hyperparathy-
roidism, is an elevated serum calcium,which maybe independentlysymptomatic and
commonly presents with renal stones. Removal of the parathyroid adenomas with
normalization of serum calcium may lead to normalization ofgastrin and resolution
of the gastric hypersecretor status. Note that one of the provocative tests for
gastrinoma employs calcium infusion [30].
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ClinicalPresentation
The classical ZE syndrome presents most frequently with persistent, often multi-
ple, symptomatic duodenal ulcers which may be complicated by bleeding, perfora-
tion, orfistula. Gastriculcer is rare andwas foundinonly2 percentofourownseries.
Over 40 percent of cases are associated with esophagitis, and as many as one-third
also have diarrhea; eithermaybe the primaryor solepresentingproblem. Previously,
when gastric surgery for ulcer was being performed more frequently, ZE patients
often presented as cases of recurrent complicated marginal ulcers within weeks of
gastrectomy. Today the widespread use of acid-suppressing medications frequently
blunts the presenting features, and most ZE patients resemble ordinary duodenal
ulcer (DU). Some mayhave rather more resistant or more rapidlyrecurring DU. The
average duration of ulcer symptoms before diagnosis in the 165 patients studied at
the NIH [21] was 6.4 years. This fact supports my contention that the syndrome is
underdiagnosed because it is not being aggressively sought, even by gastroenterolo-
gists, with the result that onlyfull-blown cases are beingrecognized.
Except for those with advanced metastatic disease, all the GI pathology and
symptoms are due to acid and pepsin hypersecretion. These, in turn, are due to
unregulated hypergastrinemia, which is secreted by the gastrinoma that is out ofthe
acid-dependent feedback loop. Moreover, it seems reasonable to assume that acid
stimulation of the duodenum acts as a continuing positive feedback by releasing
more secretin from the duodenum. There does not seem to be a functional negative
feedback from the acidified duodenum in ZE, such as there is in the dog with
transplanted antrum [4]. After total gastrectomy or in ZE patients who are totally
acid-suppressed, as well as in patients with pernicious anemia who have high gastrin
and no acid, there are no symptoms attributable to hypergastrinemia. Therefore, the
entire clinical syndrome results from gastric hypersecretion. This fact allows a highly
rational approach to ZE syndrome. Adequate control of gastric secretion (to be
defined below) will therefore eliminate the clinical syndrome; malignancy is a
separate problem. Before appropriate drugs were available, total gastrectomy was
the only certain way of achieving this goal [31,32]. With H2 antagonists, the goal
could be achieved in some but not in all, but with proton pump inhibitors (omepra-
zole, lansoprazole) this goal is now fully achievable. The clinical syndromes that
demand treatment are:
Esophageal Fully 40 percent of ZE patients have significant esophagitis, some
with stricture. While the duodenal component may be (partly) treatable by H2
blockers, the esophagitis requires much more potent acid suppression. Therefore, in
anunrecognized ZEunder treatment forDU, esophagitis,which is harder tocontrol,
may progress due to undertreatment.
Peptic ulcer in ZE presents almost invariably (98 percent) as DU, frequently
classical DU, but often with features of slow healing or rapid recurrence, especially
after gastric surgery. Many present as cases of multiple ulcers, some more distal in
the duodenum and complicated bybleeding in some. The picture maybe confusedby
concomitant aspirin abuse, which may also cause treatment resistance, multiple
ulcers, and rapid recurrence, as described above [33].
Intestinal Hypersecretion of acid results in a low pH for a variable distance
down the jejunum, with injury to the jejunal mucosa, consequent diarrhea, and
malabsorption which may be severe. Inactivation of pancreatic enzymes at low pH
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contributes to diarrhea through maldigestion offood. Such patients may lose a great
deal ofweight.
Elimination ofacid hypersecretion leads to cure ofall three categories ofupper GI
pathology.
NaturalHistory
Survival has been studied by several centers, with an average reported survival of
62-75 percent at five years and 50 percent at ten years and for all cases. These
findings have been broken down by Jensen and Gardner [21] in two alternative
analyses. (a) For those operated on for tumor diagnosis and resection where
possible: as expected, unresectable tumors had the worst prognosis, with an average
40percent survival atfiveyears; butwith no tumorfound ortumor resected therewas
60-100percent survival at tenyears. (b) According to MEN-I status: forpatientswith
MEN-I, there was 62-85 percent survival at ten years and for non-MEN patients
40-65 percent survival at ten years. Apart from malignancy and fatal metastatic
disease (- 10 percent ofmy patients), most ZE syndromes may kill the patient from
complications ofupper GI mucosal disease-bleeding orperforation, stricture ofthe
esophagus, severe malnutrition. Patientswith ZE syndrome are at great riskfrom the
often misguided and inadequate surgical procedures undertaken without proper
pre-operative diagnosis or preparation.
Diagnosis
Every patient presenting with esophagitis, duodenal ulcer, or chronic diarrhea
should have a fasting serum gastrin measured. The measurement should be made
before beginning antisecretory treatment, but can be obtained after treatment has
begun. If mildly elevated to between 100 and 150 pg/ml (normal < 100 pg/ml), the
test should be repeated after medication iswithdrawn.
There are many causes for elevated gastrin [34]. The most common confounding
cause is food in the stomach, whether from non-fasting or from gastric retention.
Other causes particularly include hypochlorhydria or achlorhydria (e.g., pernicious
anemia) inwhich serum gastrin may reach 6,000 pg/ml.
If, in the correct clinical setting, an elevated gastrin is found, a gastric analysis
should be obtained. The usual finding is a basal (fasting) one-hour acid output
(BAO) of > 15 mEq/hour, though a number of unoperated ZE patients have lower
values. After gastric surgery for ulcer disease, BAO .5 mEq/hour is supportive of
the diagnosis. Even if a gastric analysis cannot be obtained, an untreated gastric
content pH >3.5 rules out hypersecretion. It must be emphasized that any gastric
acid studies must be performed after the patient is more than two days off H2
blockers and more than eight days offomeprazole.
When serumgastrin is >250pg/ml and acid output is appropriate, no further tests
need to be done. When gastrin levels are 100-250, and gastric acid output elevated,
even if BAO is under 15 mEq/hour, a provocative test for gastrinoma is generally
required. Two tests can be used-secretin or intravenous calcium provocation, and
of these the secretin test is easier to perform, better standardized, and is generally
preferred [30]. Duplicate fasting values are obtained before intravenous bolus
injection of secretin, with measurement ofgastrin at 2, 5, 10, 15, and 20 minutes. A
rise of > 110 pg/ml at two or five minutes was positive evidence ofgastrinoma in 93
percent of ZE patients [30]. Jensen and Gardner [21] recommend a rise of . 200
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pg/ml to rule out false-positives. None of 72 duodenal ulcer patients in my labora-
tory, however, had a serum gastrin rise of > 100 pg/ml. Therefore, we feel that a
rise .100 pg/ml, especially when combined with typical gastric hypersecretion,
would be adequate for the diagnosis ofgastrinoma. A small number ofpatients with
gastrinoma may have a normal basal serum gastrin, though these are also generally
secretin-positive. Meal stimulation may increase serum gastrin significantly (> 100
percent) in as many as 30 percent ofZEpatients. Thus, the test isoflittlevalue in the
differential diagnosis of antral G-cell hyperplasia and gastrinoma. The increased
gastrin response to food inH.pylon-infected stomachs adds further confusion to the
picture, but apparently H. pyloni does not cause acid hypersecretion, since eradica-
tion leads to reduction ofgastrin but no change in acid output. Acid secretion studies
are essential to evaluate properly the significance of an elevated serum fasting
gastrin.
Hypersecretion of acid > 15 mEq/hour is considered the hallmark of ZE syn-
drome. In 100 patients with DU, and BAO >15 mEq/hour, whom we studied,
however, 67 did not have evidence for gastrinoma. The greater majority of the
non-ZE hypersecreting patients (95 percent) were men, and in those in whom a
vagotomy was performed, BAO was reduced to <3 mEq/hour [35]. Three of the
non-ZE hypersecretors had hyperhistaminemia (systemic mastocytosis in two and
basophilic leukemia in one). All hypersecretors require continuous therapy, how-
ever, as do those whose hypersecretion is due to gastrinemia. The non-ZE hyperse-
cretors are amenable to treatment by fundicvagotomy as an alternative to long-term
acid-suppressingtherapy [35], whereasvagotomy in ZE isonlyofmodestbenefit, and
does not eliminate the need for continuous medical treatment.
Treatment
Even though most ZE syndrome patients can be partly or even wholly controlled
with H2 antagonists, many required large doses (up to 10-12 g ofcimetidine/day and
a four-hour dose schedule) or the addition ofanticholinergics [21]. Generally it was
considered adequate to reduce gastric acid to < 10 mEq/hour before the next dose,
but that level frequently failed to heal esophagitis when present and allowed very
little therapeuticmargin,with often severe symptomaticrelapse occurringwithin one
to two days ofinterruption oftreatment. Because ofthe much greater efficacy ofthe
proton pump inhibitors (e.g., omeprazole) and theirlonger duration ofaction, itisno
longerreasonable to useH2 antagonists in ZEsyndrome. There is also no residualrole in
ZE for anticholinergics, sucralfate, prostaglandins, or somatostatin. Though patients
may use occasional doses ofantacid, continued need for antacid signifies inadequate
acid control.
Omeprazole bindsirreversibly to the proton pump enzyme H+-K+ATPase located
on the apical (luminal) membrane ofthe parietal cell. Because this is the final step in
acid secretion, omeprazole is highly effective and long-lasting; however, the optimum
dose mayvarywidely from 20 to > 120 mg/day and needs to be individualized. Ifthe
long-term management of a ZE patient is to be undertaken, facilities for measuring
acid secretion are essential. The objective of acid control is to maintain acid output
at <5 mEq/hour in the intact stomach and < 1 mEq/hour post-gastrectomy in the
hour before the next dose. Even more stringent control may be required for those
with significant esophagitis. To achieve this goal, omeprazole is given at an initial
dose of60 mg eachmorning, with adjustments ofdose down or up at intervals ofone
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FIG. 7. Distribution of individual hourly gastric pH values in ten
volunteers, each tested over 24 hours while being treated with cimetidine,
ranitidine, and omeprazole (after Walt et al. [43]). The shaded area
enclosed by the large circles connected by a solid line represents the pH
profile of the proteolytic activity of pepsin (100 percent = maximum
activity).
to two weeks. Ifthe dose required is 80 mg/day, it should be split and given every 12
hours. In our patients, the median dose for men was 60 mg/day and women 40
mg/dayfor the above targets.
In general, a dose established by this means remains stable in the long term, but
the patient should be retested three to six months after the first dose adjustment has
been completed. If the patient is still stable, the next test should be done at 12
months, and then atyearly intervals. It is likely that lesser doses might be effective in
maintaining remission after initial healing, but that possibility has not yet been
established. Endoscopy should be performed as indicated for the presenting lesions
in order to be sure that ulcers or esophagitis are healed. Beyond that, the lack of
symptoms, the resolution ofdiarrhea, andgain inweight can be expected in patients
with secretion adequately controlled. Any anemia should resolve spontaneously. In
those who have bled, aspirin should be avoided entirely.
Esophagitis is common in ZE, being present in over 40 percent of cases, and
requires even more stringent reduction of acid than does the duodenal ulcer. Thus,
omeprazole has been found to be superior to H2 antagonists in esophagitis. Since
pepsin mayplay an unrecognized but probably dominant role in esophagitis [36], the
ability of omeprazole but not H2 antagonists to elevate gastricjuice pH for most of
the 24-hour day to levels outside the optimal proteolytic range of pepsin (Fig. 7)
provides the necessary environment for healing.
Esophageal strictures should be dilated, cautiously at first while the mucosa is
inflamed, and progressively as healing is complete, to a final diameter of 20 mm.
Mucosal healing mayrequire suppression ofBAO to < 1 mEq/hour. Aftercomplete
resolution ofthe esophagitis, it may be possible to reduce the dose ofomeprazole to
allow BAO to drift up to 2-5 mEq/hour.
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SideEffects
Long-term treatment ofpatients with omeprazole [21,34] for up to eight years has
so far led to no known side effects attributable to the drug, including those seen in
female rats made achlorhydric byomeprazole [1]. Mice and other species that do not
develop such high gastrin levels with achlorhydria do not develop tumors under
similar circumstances [1,34]. Gastrinoma patients have increased numbers of ECL
cells in the gastric mucosa, as do patients with elevated gastrins due to pernicious
anemia [34]. The incidence ofcarcinoids in ZE syndrome is very low, however, and
probably confined to those with MEN-I [37], whose primary tumors are in fact also
carcinoids. There are no data to implicate omeprazole in the promotion ofECL-cell
hyperplasia orcarcinoids in man.
It is still important before the issue is considered closed to follow, carefully,
medically treated ZE cases for the development of gastric carcinoids; however, no
cases were found in one prospective study over four years [38]. Annual endoscopy is
recommended for this purpose aswell as to rule out acid/peptic mucosal damage.
Special Situations
Where patients cannot take oral medications, e.g., after abdominal or other
surgery requiring nothing-by-mouth status, or if comatose, vomiting, and the like,
omeprazole cannot be givenvia the nasogastric tube because thegranules dissolve at
neutral pH (in the suspending solution) and the drug is then destroyed by acid in the
stomach. In these cases, intravenous H2 antagonists in adequate doses need to be
given to control secretion (intravenous omeprazole is not yet available). Testing for
adequate control is mandatory; one of our patients who was placed on a respirator
for an unrelated acute illness at another institution died of a perforated DU within
days ofadmission because offailure to control acid secretion.
SurgicalManagement
Surgical management ofZE syndrome is oftwo kinds: (a) for control of secretion
[39] or treatment of ulcer complications and (b) for tumor removal [40,41]. In no
instance should surgery be undertaken, except for emergencies, until the ulcer
syndrome has been brought under control medically and the patient recovered for a
period oftwo to three months.
For Ulcer Manifestations There is no indication at present for a primary
operation to control acid secretion-neither vagotomy [39] nor total gastrectomy,
which before H2 antagonists was sometimes the only method available for effective
control of acid secretion. Total gastrectomy can only be considered for those who
cannot or will not take omeprazole [32,37]. It is clear that any lesser resection is an
invitation to disaster, and no elective ulcer or esophagitis surgery should be under-
taken without absolute knowledge of gastrinoma status. Any patient undergoing
emergency surgery for perforation or bleeding duodenal ulcer should be studied at
the earliest opportunity using the aspirate for (titrated) acid output (not pH alone)
per unit time and for serum gastrin, the level ofwhich isvalid even ifintravenous H2
antagonists are being given post-operatively. Repair of gastrocolic fistulas in ZE
patients should not be undertaken until the secretion has been controlled and
nutrition improved.
Tumor Control MEN-I In patients with hypercalcemia and ZE syndrome,
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parathyroidectomy is indicated and mayreduce the level ofgastrin and ofacid output
in most [40]. Gastrinomas, seldom if ever malignant in this syndrome, however, are
usually multiple, and are not amenable to attempted curative resection. Subtotal
pancreatectomy or Whipple's procedure is never curative and is clearly contraindi-
cated. It is not reported that anyresectionofgastrinoma leads to reduction inclinical
status ofother co-existingover-acting endocrine tumors.
Primary Gastninoma Resection In sporadic ZE syndrome (not MEN-I), the
optimal treatment would be excision of the responsible tumor. Even under ideal
circumstances, this approach is only completely successful in restoring normal
secretion in 20 percent of cases. Long-term follow-up of such cases is important
because of recurrence or persistence of hypersecretion requiring medication in as
many as two-thirds of the cases [41]. As mentioned above, MEN-I patients, who
comprise about 20 percent ofall ZE syndrome patients, are not amenable to surgical
treatment except for parathyroidectomy when indicated [40]. Of the remaining 80
percent, more than one-third already have metastases at presentation and are also
not amenable to curative resection [21], leaving a little over 55 percent, ofwhom 30
percent have no identifiable tumor found at surgery.
Pre-operative diagnostic workup should include ultrasound, abdominal CT scan,
and pancreatic and hepatic angiography. Other techniques include selective portal
venous sampling, which, though providing an improvedyield, carries significant risks
and should be practiced only in highly specialized centers [42]. Magnetic resonance
imaging has yet to be shown to be useful. Theoretically, scanning for uptake of
radiolabeled gastrin antibody or stable somatostatin analogs might localize tumors,
but this approach has not so far been adequately studied. Multiple intra- or
extra-hepatic metastases are a contraindication to surgery. Ideally, if a single tumor
can be identified and removed, the chance of cure is good. Recently it has been
recognized thatgastrinomas are frequently extrapancreatic, commonly in the duode-
nalwall and peripancreatic andperiduodenal nodes. Special attention tothese areas,
includingtransillumination ofthe duodenum at surgery, allows identification ofsome
tumors, and increases theyield [21,41]. Endoscopic-associated ultrasound mayprove
to be quite useful in the detection of tumors in the duodenal wall and in periduode-
nal and peripancreatic nodes.
It is my practice at present to recommend surgery only for those patients in whom
a solitary gastrinoma has been demonstrated by computed tomography or angiogra-
phy. It is not clearwhether the aggressive search for a resectable tumor results in an
eventual reduction in death from metastasis, since it is not even determinable
histologically whether a particular tumor is malignant. Partial pancreatectomy and
Whipple's operation are not recommended, even for unresectable gastrinoma in the
pancreas. One should separate the objective of curing the functional disorder
(hypergastrinemia) from the malignant metastasis prevention. It is apparent that
successful surgery would be a therapeutic convenience, freeing the patient from the
need for medication, but the equal goal can be readily accomplished by adequate
doses of omeprazole. Successful intervention for prevention of potentially fatal
metastatic disease has yet to be shown to be achieved by this approach.
Metastatic Gastrinoma
No chemotherapy is indicated in patients who have metastases only to regional
lymph nodes. Moreover, chemotherapy has been almost universally ineffective in
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curing the tumor, controlling the clinical syndrome, or even substantially retarding
the growth of established metastases [21]. At the same time, cases have been
reported oflong-standing stable hepaticorlymphnode metastaseswithouttherapeu-
tic intervention.
CONCLUSION
In conclusion, this review first deals with the feedback loop between gastrin and
the acid-secreting parietal cell. The ECL cell ofthe fundus is an additional target of
gastrin. Loss or over-production of gastrin on the one hand or of acid secretion on
the other has predictable consequences, and each of these is illustrated in appropri-
ate clinical models. These models include gastrinoma with unregulated gastrin
over-production and consequent hypersecretion and hyperplasia of parietal cells.
Loss of acid, as in pernicious anemia, promotes gastrin cell hyperplasia, and
hypergastrinemia, which leads to ECL hyperplasia and eventually carcinoids. This
effect is reversible upon removal ofthe gastrin.
REFERENCES
1. Larsson H, Carlsson E, Mattsson H, Lundell L, Sundler F, Sundell G, Wallmark B, Watanabe T,
Hakanson R: Plasma gastrin and gastric enterochromaffinlike cell activation and proliferation.
Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 90:391-
399, 1986
2. Mattsson H, Havu N, Brautigam J, Carlsson K, Lundell L, Carlsson E: Partial gastric corpectomy
results in hypergastrinemia and development ofgastric enterochromaffinlike-cell carcinoids in the rat.
Gastroenterology 100:311-319, 1991
3. Gerber JG, Payne NA: The role of gastric secretagogues in regulating gastric histamine release in
vivo. Gastroenterology 102:403-408, 1992
4. Sandvik AK, Waldum HL: CCK-8 (gastrin) receptor regulates gastric histamine release and acid
secretion. Am J Physiol 260:G925-G928, 1991
5. Dragstedt LR, Woodward ER, Oberhelman HAJr, Storer EH, Smith CA: Effect oftransplantation of
antrum ofstomach on gastric secretion in experimental animals. Am J Physiol 165:386-398, 1951
6. Parekh D, Lawson HH, van der Walt LA: The effect ofchronic acidification ofthe canine duodenum
on gastrin release from the antrum transplanted into the colon. Surgery 103:597-602, 1988
7. Hirschowitz BI, Molina E: Analysis of food stimulation of gastrin release in dogs by a panel of
inhibitors. Peptides 5:35-40, 1984
8. Fujita T, Kobayashi S, Muraki S, Sato K, Shimoji K: Gut endocrine cells as chemoreceptors. In Gut
Peptides. Edited by A Miyoshi. New York, Elsevier North Holland Biomedical Press, 1979, pp 47-52
9. Schubert ML, Jong MJ, Makhlouf GM: Bombesin/GRP-stimulated somatostatin secretion is medi-
ated bygastrin in the antrum and intrinsic neurons in the fundus. Am J Physiol 261:G885-G889, 1991
10. Solcia E, Fiocca R, Villani L, Gianatti A, Cornaggia M, Chiaravalli A, Curzio M, Capella C:
Morphology and pathogenesis ofendocrine hyperplasias, precarcinoid lesions, and carcinoids arising
in chronic atrophic gastritis. Scand J Gastroenterol 26:146-159, 1991
11. Borch K: Atrophic gastritis and gastric carcinoid tumors. Ann Med 21:291-297, 1989.
12. Eckhauser FE, Lloyd RV, Thompson NW, Raper SE, Vinik Al: Antrectomy for multicentric,
argyrophil gastric carcinoids: Apreliminary report. Surgery 104:1046-1053, 1988
13. Kern SE, Yardley JH, Lazenby AJ, Boitnott JK, Yang VW, Bayless TM, Sitzmann JV: Reversal by
antrectomy of endocrine cell hyperplasia in the gastric body in pernicious anemia: A morphometric
study. Mod Pathol 3:561-566, 1990
14. Richards AT, Hinder RA, Harrison AC: Gastric carcinoid tumors associated with hypergastrinemia
and pernicious anaemia-regression of tumors by antrectomy. A case report. S Afr Med J 72:51-53,
1987
15. Olbe L, Lundell L, Sundler F: Antrectomy in a patientwith ECL-cellgastric carcinoids andpernicious
anemia. Gastroenterol Int 1(Supplement 1):340, 1988
16. Hirschowitz BI, Griffith J, Pellegrin D, Cummings OW: Rapid regression ofenterochromaffinlike cell
gastric carcinoids in pernicious anemia after antrectomy. Gastroenterology 102:1409-1418, 1992HYPERGASTRINEMIA 675
17. Hakanson R, Axelson J, Tielemans Y, Johansson A-G, Willems G, Sundler F: Unilateral vagal
denervation suppresses omeprazole-induced trophiceffects on the denervated sideofthe rat stomach.
Scand J Gastroenterol 27:65-70, 1992
18. Axelson J, Hakanson R, Sundler F: Antrectomy does not accelerate reversal ofomeprazole-induced
trophic effects in the rat stomach. Scand J Gastroenterol 27:243-248, 1992
19. Card WI, Marks IN: The relationship between the acid output of the stomach following "maximal"
histamine stimulation and the parietal cell mass. Clin Sci 19:147-163, 1960
20. Raff MC: Social controls on cell survival and death. Nature 356:397-400, 1992
21. Jensen RT, Gardner JD: Zollinger Ellison syndrome: Clinical presentation, pathology, diagnosis and
treatment. In Peptic Ulcer Disease and Other Acid-Related Disorders. Edited by D Zakim, AJ
Dannenberg. NewYork, Acad Res Assoc, Inc, 1991, pp 117-121
22. Andersson S, Grossman MI: Effect ofvagal denervation ofpouches on gastric secretion in dogs with
intact or resected antrums. Gastroenterology 48:449-462, 1965
23. Hirschowitz BI, Hutchison GA: Long term effects ofhighly selective vagotomy (HSV) in dogs on acid
and pepsin secretion. Am J Dig Dis 22:81-95, 1977
24. Stabile BE, Morrow DJ, Passaro E Jr: The gastrinoma triangle: Operative implications. Am J Surg
147:25-31, 1984
25. Barton JC, Hirschowitz BI, Maton PN, Jensen RT: Bone metastases in malignant gastrinoma.
Gastroenterology 91:1179-1185, 1986
26. Chiang H-C, O'Dorisio TM, Huang SC, Maton PN, Gardner JD, Jensen RT: Multiple hormone
elevations in Zollinger-Ellison syndrome: Prospective study of clinical significance and of develop-
ment of a second symptomatic pancreatic endocrine tumor syndrome. Gastroenterology 99:1565-
1575, 1990
27. Kothary PC, Mahoney WC, Vinik Al: Identification of gastrin molecular variants in gastrinoma
syndrome. Regul Pept 17:71-84, 1987
28. Del Valle G, Sugano K, Yamada T: Progastrin and its glycine-extended posttranslational processing
intermediates in human gastrointestinal tissues. Gastroenterology 92:1908-1912, 1987
29. Wermer P: Multiple endocrine adenomatosis; Multiple hormone-producing tumours. A familial
syndrome. Clin Gastroenterol 3:671-684, 1974
30. Frucht H, HowardJM, SlaffJI, WankSA, McCarthy DM, Maton PN, Vinayek R, GardnerJD, Jensen
RT: Secretin and calcium provocative tests in the Zollinger-Ellison syndrome. A prospective study.
Ann Int Med 111:713-722, 1989
31. Thompson JC, Lewis BG, Wiener I, Townsend CM Jr: The role of surgery in the Zollinger-Ellison
syndrome. Ann Surg 197:594-607, 1983
32. Bonfils S, Jensen RT, Malagelada J, Stadil F: Zollinger-Ellison management: A protocol for strategy.
Gastronterol Int 2:9-15, 1989
33. Hirschowitz BI, Lanas A: Intractable and recurrent postsurgical peptic ulceration is due to aspirin
(ASA) abuse, much ofit surreptitious (Abstract). Gastroenterology, in press
34. Maton PN, Dayal Y: Clinical implications of hypergastrinemia. In Peptic Ulcer Disease and Other
Acid-Related Disorders. Edited by D Zakim, AJ Dannenberg. NewYork, Acad Res Assoc, Inc, 1991,
pp 213-246
35. Kirkpatrick PM Jr, Hirschowitz BI: Duodenal ulcer with unexplained marked basal gastric acid
hypersecretion. Gastroenterology 79:4-10, 1980
36. Hirschowitz BI: Pepsin in the pathogenesis of peptic ulceration. In Mechanisms of Peptic Ulcer
Healing. Edited byFHalter, AGarner, GNJTytgat. Amsterdam, The Netherlands, KluwerAcademic
Publishers, 1990, pp 183-194
37. Mignon M, Ruszniewski R, Haffar S, Rigaud D, Rene E, Bonfils S: Current approach to the
management oftumoral process in patients with gastrinoma. World J Surg 10:703-710, 1986
38. Maton PN, Lack EE, Collen MJ, Cornelius MJ, David E, Gardner JD, Jensen RT: The effect of
Zollinger-Ellison syndrome and omeprazole therapyongastricoxyntic endocrine cells. Gastroenterol-
ogy 99:943-950, 1990
39. Richardson CT, Feldman M, McClelland RN, Dickerman RM, Kumpuris D, Fordtran JS: Effect of
vagotomy in Zollinger-Ellison syndrome. Gastroenterology 77:682-686, 1979
40. Norton JA, Cornelius MJ, Doppman JL, Maton PN, GardnerJD, Jensen RT: Effectofparathyroidec-
tomy in patients with hyperparathyroidism, Zollinger-Ellison syndrome, and multiple endocrine
neoplasia type I: A prospective study. Surgery 102:958-966, 1987
41. PisegnaJR, Norton JA, Slimak GG, Metz DC, Maton PN, GardnerJD, Jensen RT: Effectsofcurative676 BASIL I. HIRSCHOWITZ
gastrinoma resection on gastric secretory function and antisecretory drug requirement in the
Zollinger-Ellison syndrome. Gastroenterology 102:767-778, 1992
42. Miller DL, Doppman JL, Metz DC, Maton PN, Norton JA, Jensen RT: Zollinger Ellison syndrome:
Technique, results and complications ofportal venous sampling. Radiology 182:235-241, 1992
43. Walt RP, Gomes MD, Wood EC, Logan LH, Pounder RE: Effect ofdaily oral omeprazole on 24 hour
intragastric acidity. Brit Med J 287:12-14, 1983